Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is -4.51% as of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
-4.51%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.75%
median of 681 covered companies
CURRENT VS SECTOR MEDIAN
+88.94%
vs the sector median at left
Lumexa Imaging Holdings, Inc. Common Stock
Market Cap
$1.03B
Return on Equity (ROE)
-4.51%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.03B
Return on Equity (ROE)
-52.47%
TTM Avg
-18.98%
3Y Avg
-16.96%
5Y Avg
-116.25%
Market Cap
$1.03B
Return on Equity (ROE)
-4.13%
TTM Avg
-0.56%
3Y Avg
-8.16%
5Y Avg
-7.12%
Market Cap
$1.03B
Return on Equity (ROE)
-11.06%
TTM Avg
-9.32%
3Y Avg
-13.81%
5Y Avg
-2.96%
Market Cap
$1.04B
Return on Equity (ROE)
-63.62%
TTM Avg
-41.08%
3Y Avg
-23.78%
5Y Avg
-22.76%
Market Cap
$1.04B
Return on Equity (ROE)
-0.69%
TTM Avg
-24.98%
3Y Avg
-8.92%
5Y Avg
-2.80%
Market Cap
$1.00B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.05B
Return on Equity (ROE)
-13.54%
TTM Avg
-40.81%
3Y Avg
-170.75%
5Y Avg
-114.78%
Market Cap
$991.81M
Return on Equity (ROE)
-32.27%
TTM Avg
-24.43%
3Y Avg
-32.70%
5Y Avg
-40.03%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI) | $1.03B | -4.51% | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.03B | -52.47% | -18.98% | -16.96% | -116.25% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.03B | -4.13% | -0.56% | -8.16% | -7.12% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.03B | -11.06% | -9.32% | -13.81% | -2.96% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.04B | -63.62% | -41.08% | -23.78% | -22.76% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | -0.69% | -24.98% | -8.92% | -2.80% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.00B | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | -13.54% | -40.81% | -170.75% | -114.78% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $991.81M | -32.27% | -24.43% | -32.70% | -40.03% |
| Pacira BioSciences, Inc. (PCRX)vs › | $982.98M | 2.18% | -5.89% | -1.23% | 4.05% |
ROE
-4.5%
ROA
-1.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -4.51% |
